Answers are grounded in this paper and cite their sources.
Reliable in vitro evaluation of anti-influenza activity in chemically complex natural products is vulnerable to false-positive interpretation when changes in host-cell metabolism, vehicle effects, batch variability, or assay-specific signals are treated as direct evidence of antiviral efficacy. Melaleuca (M.) alternifolia essential oil (TTO), influenza A/PR/8/34 (H1N1), and MDCK cells are used here as an illustrative system for this challenge. We present an integrated approach linking test-material definition, host-cell compatibility, a conservative non-cytotoxicity gate, inoculum standardization, treatment timing, and complementary virological readouts. Infectious-virus measurement is treated as the principal functional antiviral endpoint, whereas hemagglutination assay and RT-qPCR provide complementary virological evidence, MTT provides a separate host-cell metabolic readout and is not evidence of virus-specific inhibition. The integrated assessment combines chemical definition, host-cell compatibility, treatment timing, and complementary virological readouts while keeping preliminary screening observations separate from claims of quantitative potency, maximal efficacy, target engagement, or regulated cell death that would require dedicated evidence.
No takes yet. Share an insight, caveat, or question.
Ebrahimi et al. (2026) studied this question.